Teva And Fosun Pharma Team Up To Develop TEV-56278, A New Anti-PD1-IL2 Immuno-Oncology Drug

Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have entered into a strategic partnership to advance the development of TEV-56278, an investigational anti-PD1-IL2 ATTENUKINE therapy. The collaboration will be carried out through their respective subsidiaries and is aimed at accelerating the clinical development of this novel cancer immunotherapy.

TEV-56278 is based on Teva’s proprietary ATTENUKINE technology, which is designed to offer a new mechanism of action for cancer treatment. The therapy targets PD-1 positive T cells and delivers IL-2 selectively to these immune cells, aiming to enhance their tumor-fighting capabilities while reducing systemic side effects. This targeted delivery approach could potentially provide improved efficacy with lower toxicity across a broad range of cancers.

Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer, said in a statement, “This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline. TEV-56278 demonstrates the strength of Teva’s innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.”

Xingli WANG, MD, PhD, Executive President of Fosun Pharma and CEO of the Global R&D Center, stated, "We are pleased to partner with Teva on the development of TEV-56278. This collaboration brings together Teva's expertise in innovative drug development with Fosun Pharma's strong oncology development experience and commercial capabilities in the China market, creating a powerful synergy to accelerate the delivery of this important therapy to patients globally.”

As part of the agreement, Fosun Pharma has received an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva will retain full rights to develop, manufacture, and commercialize the therapy in all other regions globally.

This partnership is expected to significantly contribute to the global development of TEV-56278 by allowing Teva to utilize clinical data generated by Fosun Pharma in other markets. The collaboration combines Teva’s innovative technology with Fosun Pharma’s regional expertise, aiming to bring a promising new immunotherapy option to cancer patients around the world.